Brief: Celularity Receives Fast Track Designation From U.S. FDA For Cynk-001
27/12/2021 13:26
Dec 27 (Reuters) - Celularity Inc CELU.O :
* CELULARITY RECEIVES FAST TRACK DESIGNATION FROM U.S. FDA
FOR ITS
NK CELL THERAPY CYNK-001 IN DEVELOPMENT FOR THE TREATMENT OF AML
Source text for Eikon: ID:nGNX9LzxBj
Further company coverage: CELU.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Celularity
See all newsU.S. STOCKS ON THE MOVE-BWX Technologies, Synopsys,Burlington Stores
U.S. STOCKS ON THE MOVE-Jazz Pharmaceuticals, Celularity, Infleqtion
Celularity hits over 4-month high on deal to manufacture MuseCell's cell therapy platform
Celularity rises on deal to manufacture MuseCell's cell therapy platform
Brief: Celularity And MuseCell Innovations® Announce U.S. Manufacturing Collaboration For The Dezawa Musecell® Platform